delgocitinib (Us8609647) Patent Information

Patent US8609647, related to delgocitinib, is a key document in understanding the intellectual property surrounding this Janus kinase (JAK) inhibitor. Delgocitinib is being developed for various autoimmune and inflammatory conditions.

What is Us8609647 about?

U.S. Patent 8,609,647 describes certain compounds, including delgocitinib, and their use in treating conditions mediated by Janus kinases (JAKs). The patent focuses on the chemical structures and therapeutic applications of these JAK inhibitors. DrugPatentWatch.com provides information on patents like this, detailing their status and expiration dates [1].

When does the patent for delgocitinib expire?

The expiration of U.S. Patent 8,609,647 for delgocitinib depends on its specific filing date, grant date, and any potential patent term extensions. Generally, utility patents in the United States have a term of 20 years from the date on which the application was filed. However, specific circumstances can lead to extensions. Information on patent expiration can be found on sites like DrugPatentWatch.com [1].

How is delgocitinib used?

Delgocitinib is a topical JAK inhibitor being investigated for the treatment of atopic dermatitis and other inflammatory skin diseases. It works by inhibiting specific JAK enzymes involved in the inflammatory signaling pathways. Clinical trials are ongoing to establish its efficacy and safety for various indications.

Who is developing delgocitinib?

Torii Pharmaceutical Co., Ltd. is the company developing delgocitinib. They have been conducting clinical studies to evaluate its potential in treating conditions like atopic dermatitis.

What are the potential side effects of delgocitinib?

As with many medications, delgocitinib may have side effects. Common side effects observed in clinical trials for topical JAK inhibitors can include application site reactions such as redness, itching, or burning. Systemic side effects are also a consideration for JAK inhibitors, and patients and healthcare providers monitor for these.

Can generic versions of delgocitinib be made after patent expiry?

Following the expiration of relevant patents and loss of any market exclusivity, generic manufacturers can potentially develop and market bioequivalent versions of delgocitinib. This process typically involves demonstrating similarity to the reference drug and obtaining regulatory approval.

How does delgocitinib compare to other JAK inhibitors?

Delgocitinib is a topical JAK inhibitor, distinct from orally administered JAK inhibitors that are already approved for certain autoimmune diseases. The topical formulation aims to deliver the medication directly to the affected skin, potentially minimizing systemic exposure and associated risks. Different JAK inhibitors target varying combinations of JAK enzymes, which can influence their efficacy and side effect profiles.

What is the regulatory status of delgocitinib?

Delgocitinib is undergoing clinical development and has not yet received widespread regulatory approval for all intended indications. Regulatory bodies like the U.S. Food and Drug Administration (FDA) will review clinical trial data to determine its approvability for specific uses.

Sources

1. https://drugpatentwatch.com/